Cargando…
Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer
Chemo-resistant breast cancer is a major barrier to curative treatment for a significant number of women with breast cancer. Neoadjuvant chemotherapy (NACT) is standard first- line treatment for most women diagnosed with high-risk TNBC, HER2+, and locally advanced ER+ breast cancer. Current clinical...
Autores principales: | Gupta, Gagan, Lee, Caroline Dasom, Guye, Mary L, Van Sciver, Robert E, Lee, Michael P, Lafever, Alex C, Pang, Anthony, Tang-Tan, Angela M, Winston, Janet S, Samli, Billur, Jansen, Rick J, Hoefer, Richard A, Tang, Amy H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295150/ https://www.ncbi.nlm.nih.gov/pubmed/32542231 http://dx.doi.org/10.36959/739/525 |
Ejemplares similares
-
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
por: Gupta, Gagan K., et al.
Publicado: (2020) -
Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer
por: Tang, Amy H., et al.
Publicado: (2022) -
Lung cancer metastasis to the breast mimicking inflammatory breast carcinoma on imaging
por: Malek, Daniel, et al.
Publicado: (2019) -
A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
por: Van Sciver, Robert E., et al.
Publicado: (2018) -
Bayesian forecasting of tumor size metrics and overall survival
por: Krishnan, Sreenath M., et al.
Publicado: (2022)